{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T10:38:59Z","timestamp":1786358339506,"version":"build-2736575974"},"reference-count":72,"publisher":"BMJ","issue":"7058","license":[{"start":{"date-parts":[[1996,9,14]],"date-time":"1996-09-14T00:00:00Z","timestamp":842659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ"],"accepted":{"date-parts":[[1996,6,21]]},"published-print":{"date-parts":[[1996,9,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objectives<\/jats:bold>\n                    : Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely. A systematic overview (meta-analysis) of their results is needed, in particular to assess the clinical effects of adding heparin to aspirin.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design<\/jats:bold>\n                    : Computer aided searches, scrutiny of reference lists, and inquiry of investigators and companies were used to identify potentially eligible studies. On central review, 26 studies were found to involve unconfounded randomised comparisons of anticoagulant therapy versus control in suspected acute myocardial infarction. Additional information on study design and outcome was sought by correspondence with study investigators.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Subjects<\/jats:bold>\n                    : Patients with suspected acute myocardial infarction.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Interventions<\/jats:bold>\n                    : No routine aspirin was used among about 5000 patients in 21 trials (including half of one small trial) that assessed heparin alone or heparin plus oral anticoagulants, and aspirin was used routinely among 68 000 patients in six trials (including the other half of one small trial) that assessed the addition of intravenous or high dose subcutaneous heparin.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Main outcome measurements<\/jats:bold>\n                    : Death, reinfarction, stroke, pulmonary embolism, and major bleeds (average follow up of about 10 days).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : In the absence of aspirin, anticoagulant therapy reduced mortality by 25% (SD 8%; 95% confidence interval 10% to 38%; 2P = 0.002), representing 35 (11) fewer deaths per 1000. There were also 10 (4) fewer strokes per 1000 (2P = 0.01), 19 (5) fewer pulmonary emboli per 1000 (2P&lt;0.001), and non-significantly fewer reinfarctions, with about 13 (5) extra major bleeds per 1000 (2P = 0.01). Similar sized effects were seen with the different anticoagulant regimens studied. In the presence of aspirin, however, heparin reduced mortality by only 6% (SD 3%; 0% to 10%; 2P = 0.03), representing just 5 (2) fewer deaths per 1000. There were 3 (1.3) fewer reinfarctions per 1000 (2P = 0.04) and 1 (0.5) fewer pulmonary emboli per 1000 (2P = 0.01), but there was a small non-significant excess of stroke and a definite excess of 3 (1) major bleeds per 1000 (2P&lt;0.0001).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    : The clinical evidence from randomised trials does not justify the routine addition of either intravenous or subcutaneous heparin to aspirin in the treatment of acute myocardial infarction (irrespective of whether any type of fibrinolytic therapy is used).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:boxed-text position=\"float\">\n                      <jats:sec>\n                        <jats:title>Key messages<\/jats:title>\n                        <jats:list list-type=\"bullet\">\n                          <jats:list-item>\n                            <jats:p>Heparin seemed to be useful among patients with suspected acute myocardial infarction who, in the past, had received neither aspirin nor fibrinolytic therapy<\/jats:p>\n                          <\/jats:list-item>\n                          <jats:list-item>\n                            <jats:p>The available evidence from clinical trials does not justify the routine addition of intravenous or subcutaneous heparin to aspirin in the treatment of acute myo- cardial infarction (whether or not any type of fibrinolytic therapy is used)<\/jats:p>\n                          <\/jats:list-item>\n                        <\/jats:list>\n                      <\/jats:sec>\n                    <\/jats:boxed-text>\n                  <\/jats:p>","DOI":"10.1136\/bmj.313.7058.652","type":"journal-article","created":{"date-parts":[[2011,10,31]],"date-time":"2011-10-31T16:59:52Z","timestamp":1320080392000},"page":"652-659","source":"Crossref","is-referenced-by-count":143,"title":["Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials"],"prefix":"10.1136","volume":"313","author":[{"given":"Rory","family":"Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"MacMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Flather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Remvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svend","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Appleby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Peto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[1996,9,14]]},"reference":[{"key":"2025122311093142000_313.7058.652.1","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.","volume":"ii","year":"1988","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.81"},{"key":"2025122311093142000_313.7058.652.3","doi-asserted-by":"crossref","unstructured":"Collins R Peto R Baigent C Sleight P .Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1996 (in press)","DOI":"10.1056\/NEJM199703203361207"},{"key":"2025122311093142000_313.7058.652.4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(72)93016-4","article-title":"Low dose heparin after myocardial infarction.","volume":"ii","author":"Handley","year":"1972","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM197303152881103","article-title":"Small subcutaneous doses of heparin in prevention of venous thrombosis.","volume":"288","author":"Gallus","year":"1973","journal-title":"N Engl J Med"},{"key":"2025122311093142000_313.7058.652.6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S0140-6736(73)92597-X","article-title":"A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction.","volume":"ii","author":"Warlow","year":"1973","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/bmj.1.6052.18","article-title":"Preventing thromboembolism after myocardial infarction: effect of low dose heparin or smoking.","volume":"i","author":"Emerson","year":"1977","journal-title":"BMJ"},{"key":"2025122311093142000_313.7058.652.8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1445-5994.1982.tb03831.x","article-title":"Comparison of sodium and calcium heparin in prevention of venous thromboembolism.","volume":"12","author":"Cade","year":"1982","journal-title":"Aust NZ J Med"},{"key":"2025122311093142000_313.7058.652.9","first-page":"1053","article-title":"Lav-dosis heparinbehandling som profylakse mod dyb venetrombose ved akut myokardieinfarkt.","volume":"145","author":"Remvig","year":"1983","journal-title":"Ugeskr Laeger"},{"key":"2025122311093142000_313.7058.652.10","first-page":"179","article-title":"Low-dose heparin in the prevention of thrombotic complications following acute myocardial infarction.","volume":"3","author":"Zawilska","year":"1989","journal-title":"Cor Vasa"},{"key":"2025122311093142000_313.7058.652.11","first-page":"102","article-title":"Heparin administration after acute myocardial infarction.","volume":"20","author":"Carleton","year":"1960","journal-title":"N Engl J Med"},{"key":"2025122311093142000_313.7058.652.12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.0954-6820.1969.tb01515.x","article-title":"Coronary occlusion treated with small doses of heparin.","volume":"186","author":"Steffensen","year":"1969","journal-title":"Acta Med Scand"},{"key":"2025122311093142000_313.7058.652.13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.2.5811.436","article-title":"Heparin in the prevention of deep vein thrombosis after myocardial infarction.","volume":"ii","author":"Handley","year":"1972","journal-title":"BMJ"},{"key":"2025122311093142000_313.7058.652.14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0735-1097(86)80061-4","article-title":"Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction.","volume":"8","author":"Gueret","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"2025122311093142000_313.7058.652.15","first-page":"634","article-title":"Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction.","volume":"8","author":"Collins","year":"1987","journal-title":"Eur Heart J"},{"key":"2025122311093142000_313.7058.652.16","first-page":"13","article-title":"Valor de la anticoagulacion precoz en la prevencion de la trombosis intraventricular despues de un primer infarto del miocardio: estudio prospectivo y randomizado.","volume":"116","author":"Diaz","year":"1988","journal-title":"Rev Med Chile"},{"key":"2025122311093142000_313.7058.652.17","first-page":"182","article-title":"Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction.","volume":"ii","year":"1989","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(90)90525-6"},{"key":"2025122311093142000_313.7058.652.19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1972.03210050013003"},{"key":"2025122311093142000_313.7058.652.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1973.03220340034009"},{"key":"2025122311093142000_313.7058.652.21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM197304192881604","article-title":"Prophylactic anticoagulant therapy in the prevention of calf-vein thrombosis after myocardial infarction.","volume":"288","author":"Wray","year":"1973","journal-title":"N Engl J Med"},{"key":"2025122311093142000_313.7058.652.22","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(80)90729-2"},{"key":"2025122311093142000_313.7058.652.23","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)90959-2"},{"key":"2025122311093142000_313.7058.652.24","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(87)90708-3"},{"key":"2025122311093142000_313.7058.652.25","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.67.2.122"},{"issue":"suppl I","key":"2025122311093142000_313.7058.652.26","first-page":"259","article-title":"Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction: results of a double blind randomized study (OSIRIS).","volume":"86","author":"Col","year":"1992","journal-title":"Circulation"},{"key":"2025122311093142000_313.7058.652.27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0735-1097(94)90496-0","article-title":"A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University clinical cardiology study (DUCCS) 1.","volume":"23","author":"O'Connor","year":"1994","journal-title":"J Am Coll Cardiol"},{"key":"2025122311093142000_313.7058.652.28","first-page":"65","article-title":"GISSI-2: randomised trial of intravenous alteplase versus intravenous streptokinase in acute myocardial infarction.","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.29","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91590-7"},{"key":"2025122311093142000_313.7058.652.30","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91893-D"},{"key":"2025122311093142000_313.7058.652.31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/sim.4780060306","article-title":"Why do we need systematic overviews of randomized trials?","volume":"6","author":"Peto","year":"1987","journal-title":"Stat Med"},{"key":"2025122311093142000_313.7058.652.32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/sim.4780060308","article-title":"Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews.","volume":"6","author":"Collins","year":"1987","journal-title":"Stat Med"},{"key":"2025122311093142000_313.7058.652.33","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM197711172972004","article-title":"Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction.","volume":"297","author":"Chalmers","year":"1977","journal-title":"N Engl J Med"},{"issue":"suppl II","key":"2025122311093142000_313.7058.652.34","first-page":"98","article-title":"Reduction in major morbidity and mortality by heparin in acute myocardial infarction.","volume":"78","author":"MacMahon","year":"1988","journal-title":"Circulation"},{"issue":"suppl I","key":"2025122311093142000_313.7058.652.35","first-page":"259","article-title":"Heparin in the presence or absence of antiplatelet therapy: an overview of randomized trials in acute myocardial infarction.","volume":"86","author":"MacMahon","year":"1992","journal-title":"Circulation"},{"key":"2025122311093142000_313.7058.652.36","first-page":"653","article-title":"Prevenzione della trombosi venosa profonda con eparina a basse dosi in pazienti con infarto miocardico acuto non complicato.","volume":"34","author":"Prandoni","year":"1986","journal-title":"Minerva Cardioangiologica"},{"key":"2025122311093142000_313.7058.652.37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0002-8703(66)90655-7","article-title":"Anticoagulants in acute myocardial infarction. The failure of anticoagulants to alter mortality in a randomized series.","volume":"71","author":"Wasserman","year":"1956","journal-title":"Am Heart J"},{"issue":"suppl 330","key":"2025122311093142000_313.7058.652.38","first-page":"5","article-title":"Effect of long-term treatment with dicoumarol in myocardial infarction.","volume":"158","author":"Bjerkelund","year":"1957","journal-title":"Acta Med Scand"},{"key":"2025122311093142000_313.7058.652.39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(62)92540-0","article-title":"Long-term anticoagulant therapy after myocardial infarction.","volume":"ii","author":"Harvald","year":"1962","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.0954-6820.1967.tb10881.x","article-title":"A double-blind trial of long-term anticoagulant treatment after myocardial infarction.","volume":"182","author":"Loeliger","year":"1967","journal-title":"Acta Med Scand"},{"key":"2025122311093142000_313.7058.652.41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.0954-6820.1969.tb07299.x","article-title":"Anticoagulant treatment of acute coronary thrombosis.","volume":"185","author":"Sorensen","year":"1969","journal-title":"Acta Med Scand"},{"key":"2025122311093142000_313.7058.652.42","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/clc.4960101018","article-title":"Treatment of acute myocardial infarction with heparin at low doses.","volume":"10","author":"Ruggiero","year":"1987","journal-title":"Clin Cardiol"},{"key":"2025122311093142000_313.7058.652.43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0002-9149(64)90106-7","article-title":"Preinfarction syndrome\u2014management and follow-up.","volume":"14","author":"Vakil","year":"1964","journal-title":"Am J Cardiol"},{"key":"2025122311093142000_313.7058.652.44","first-page":"567","article-title":"Long-term anticoagulant therapy after myocardial infarction.","volume":"83","author":"MacMillan","year":"1960","journal-title":"Can Med Assoc J"},{"issue":"suppl 359","key":"2025122311093142000_313.7058.652.45","first-page":"5","article-title":"Long-term anticoagulant therapy in angina pectoris and myocardial infarction. A clinical trial of intensive versus moderate treatment.","volume":"168","author":"Borchgrevink","year":"1960","journal-title":"Acta Med Scand"},{"key":"2025122311093142000_313.7058.652.46","first-page":"1345","article-title":"Initial heparin therapy in acute myocardial infarction.","volume":"90","author":"Brown","year":"1964","journal-title":"Can Med Assoc J"},{"key":"2025122311093142000_313.7058.652.47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/j.1326-5377.1967.tb73912.x","article-title":"A controlled trial of long-term treatment with anticoagulants after myocardial infarction in 412 male patients.","volume":"54","author":"Lovell","year":"1967","journal-title":"Med J Aust"},{"key":"2025122311093142000_313.7058.652.48","first-page":"335","article-title":"Assessment of short-term anticoagulant administration after cardiac infarction.","volume":"i","year":"1969","journal-title":"BMJ"},{"key":"2025122311093142000_313.7058.652.49","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.35.5.538"},{"key":"2025122311093142000_313.7058.652.50","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90196-7"},{"key":"2025122311093142000_313.7058.652.51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902093200604"},{"key":"2025122311093142000_313.7058.652.52","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.79.2.281"},{"key":"2025122311093142000_313.7058.652.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011223232101"},{"key":"2025122311093142000_313.7058.652.54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309023291001"},{"key":"2025122311093142000_313.7058.652.55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520440040034"},{"key":"2025122311093142000_313.7058.652.56","unstructured":"Early Breast Cancer Trialists' Collaborative Group, Treatment of early breast cancer Vol 1. Worldwide evidence 1985\u20131990.Oxford: Oxford University Press,1990."},{"key":"2025122311093142000_313.7058.652.57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440200057023"},{"key":"2025122311093142000_313.7058.652.58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805053181805"},{"key":"2025122311093142000_313.7058.652.59","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6923.235"},{"key":"2025122311093142000_313.7058.652.60","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)89305-8"},{"key":"2025122311093142000_313.7058.652.61","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/0140-6736(93)90707-N","article-title":"Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction?","volume":"341","author":"Ridker","year":"1993","journal-title":"Lancet"},{"key":"2025122311093142000_313.7058.652.62","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400020085018"},{"key":"2025122311093142000_313.7058.652.63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292204"},{"issue":"suppl I","key":"2025122311093142000_313.7058.652.64","first-page":"258","article-title":"APTTs after thrombolysis and standard intravenous heparin are often low and correlate with body weight, age and sex: experience from the GUSTO Trial.","volume":"86","author":"Granger","year":"1992","journal-title":"Circulation"},{"key":"2025122311093142000_313.7058.652.65","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0735-1097(92)90001-4","article-title":"Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).","volume":"20","author":"Arnout","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2025122311093142000_313.7058.652.66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0735-1097(92)90133-8","article-title":"Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency.","volume":"20","author":"Hsia","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"2025122311093142000_313.7058.652.67","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1161\/01.CIR.90.4.1631","article-title":"Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes.","volume":"90","year":"1994","journal-title":"Circulation"},{"key":"2025122311093142000_313.7058.652.68","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.90.4.1624"},{"key":"2025122311093142000_313.7058.652.69","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1161\/01.CIR.90.4.1638","article-title":"Safety observations from the pilot phase of the randomised r-hirudin for improvement of thrombolysis (HIT-III) study.","volume":"90","author":"Neuhaus","year":"1994","journal-title":"Circulation"},{"issue":"suppl D","key":"2025122311093142000_313.7058.652.70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/16.suppl_D.2","article-title":"Current and future perspectives on antithrombotic therapy of acute myocardial infarction.","volume":"16","author":"Hennekens","year":"1995","journal-title":"Eur Heart J"},{"key":"2025122311093142000_313.7058.652.71","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.3.1449"},{"key":"2025122311093142000_313.7058.652.72","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520430045037"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.313.7058.652","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.313.7058.652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:09:41Z","timestamp":1766516981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.313.7058.652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,9,14]]},"references-count":72,"journal-issue":{"issue":"7058","published-online":{"date-parts":[[1996,9,14]]},"published-print":{"date-parts":[[1996,9,14]]}},"alternative-id":["10.1136\/bmj.313.7058.652"],"URL":"https:\/\/doi.org\/10.1136\/bmj.313.7058.652","relation":{},"ISSN":["0959-8138","1468-5833"],"issn-type":[{"value":"0959-8138","type":"print"},{"value":"1468-5833","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,9,14]]}}}